Characteristics of Products of Fibrinogen Origin in the Presence of Anti- SARS-CoV-2 IgG in the Bloodstream
Authors:
- Antonina RachkovskaARAntonina Rachkovska
- Daryna KrenytskaDKDaryna Krenytska
- Vitalii KarbovskyyVKVitalii Karbovskyy
- Tetiana HalenovaTHTetiana Halenova
- Nataliia RakshaNRNataliia Raksha
- Olexii SavchukOSOlexii Savchuk
- Dmytro LiubenkoDLDmytro Liubenko
- Tetyana FalalyeyevaTFTetyana Falalyeyeva
- Ludovico AbenavoliLudovico Abenavoli
- 1 February 2023
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Reviews on Recent Clinical Trials
- Vol. 18 (1) , 69-75
Abstract
Background: The hemostasis system has been extensively investigated in patients in the acute phase of coronavirus disease 2019 (COVID-19). In contrast, the post-COVID syndrome is a poorly known entity, and there is a lack of information on the mechanisms underlying the hemostasis abnormalities in the post-COVID period. Aim: To analyze the potential changes in the parameters of the hemostasis system in the post- COVID period in the plasma of donors with different titers of anti-SARS-CoV-2 IgG. Methods: The plasma from 160 donors who had recovered from COVID infection was used in the study. Based on the results of the Abbott SARS-CoV-2 IgG serological assay, all donors were divided into several groups: 5 ± 3 (n = 20); 55 ± 5 (n = 20); 65 ± 5 (n = 20); 75 ± 5 (n = 20); 85 ± 5 (n = 20); 95 ± 5 (n = 20); 125 ± 5 (n = 20); 175 ± 5 (n = 20) Index (S/C). A total of 20 healthy individuals without anti-SARS-CoV-2 IgG constituted the control group. Key laboratory parameters, such as fibrinogen concentrations, soluble fibrin monomer complex (SFMCs), and Ddimer, were investigated. In addition, the qualitative composition of the fraction of SFMCs was analyzed. Results: The slight increase in the concentration of fibrinogen, SFMCs, and D-dimers in some donor groups have been found, which could cause the development of hemostasis disorders. In the fraction of SFMCs, the increase in the number of protein fragments with a molecular weight of less than 250 kDa and an increase in the level of proteins with a molecular weight of more than 270 kDa was revealed. Conclusion: The obtained results indicated the relationship between the changes in the parameters of the hemostasis system and the titers of anti-SARS-CoV-2 IgG in donors in the post-COVID period. It can be assumed that donors with higher titers of anti-SARS-CoV-2 IgG (>55 ± 5 Index (S/C)) are more prone to hemostasis abnormalities in the post-COVID period since a pronounced imbalance in the levels of SFMCs and D-dimer characterizes them. The appearance of protein fragments of different molecular weights in the fraction of SFMC points to uncontrolled activation of biochemical processes involving molecules of fibrinogenic origin. Additional studies are required to elucidate the role of anti-SARS-CoV-2 IgG in the post-COVID period.Keywords
This publication has 17 references indexed in Scilit:
- Presence of Extra-Criteria Antiphospholipid Antibodies Is an Independent Risk Factor for Ischemic StrokeFrontiers in Cardiovascular Medicine, 2021
- Modulation of Hemostasis in COVID-19; Blood Platelets May Be Important Pieces in the COVID-19 PuzzlePathogens, 2021
- SARS-CoV-2 and coagulation disorders in different organsLife Sciences, 2020
- Hemostatic Abnormalities in COVID-19: An UpdateIndian Journal of Hematology and Blood Transfusion, 2020
- Haematological manifestations, mechanisms of thrombosis and anti-coagulation in COVID-19 disease: A reviewAnnals of Medicine & Surgery, 2020
- Coagulopathy of Coronavirus Disease 2019Critical Care Medicine, 2020
- Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumoniaJournal of Thrombosis and Haemostasis, 2020
- Effect of fibrinogen, fibrin, and fibrin degradation products on transendothelial migration of leukocytesThrombosis Research, 2018
- Effect of IgG from multiple sclerosis patients on amidolytic activity of coagulation and anticoagulation factors of hemostasisBiomedical Research and Therapy, 2017
- Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndromeThrombosis and Haemostasis, 2014